Bluebird's pop from investor presentations may have run its course

Shares of bluebird bio (BLUE -18.4%) are down big on a 50% surge in volume after the company wrapped up its third investor presentation this morning at the UBS Healthcare Conference. The stock had been on a tear since the day after its first presentation on May 8 at the Deutsche Bank Health Care Conference, followed by a second presentation on May 14 at Bank of America's Healthcare Conference. Shares peaked at $27.65 on May 20 representing a 59% gain from the May 9 low of $17.40. Shares are still down 58% from the July 17 high of $36.25.

From other sites
Comments (2)
  • Henhousecocks
    , contributor
    Comments (19) | Send Message
    Can anyone make a practical consorted effort at explaining this dramatic price decrease? What factors drove this reduction and should shareholders dig in or flee? Are further stock price reductions in order or will this stock stabilize rather quickly?
    21 May 2014, 02:05 PM Reply Like
  • vireoman
    , contributor
    Comments (1269) | Send Message
    In biotech these days, every action is followed by an equal and opposite reaction. People are making money on them these days, but it ain't long-term investors.
    21 May 2014, 04:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs